GYRE THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 13, 2026
GYRE$4.23-9.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statem ents of Cash Flows
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating Activities | ||
| Net income from operations | $9,880 | $17,898 |
| Adjustments to reconcile net income to net cash provided (used) by operating activities: | ||
| Stock-based compensation | 7,157 | 831 |
| Depreciation and amortization | 2,481 | 1,549 |
| Noncash lease expense | 777 | 672 |
| Amortization of land use rights | 39 | 39 |
| Deferred income taxes, net | (1,109) | (1,002) |
| Bad debt expense and other non-cash items | (63) | 170 |
| Accrued interest on bank deposit | 28 | (1,046) |
| Change in fair value of receivables from GCBP | (39) | (239) |
| Change in fair value of derivative liabilities | 39 | 239 |
| Change in fair value of warrant liability | (2,707) | (7,167) |
| Equity loss of unconsolidated affiliates | 77 | 37 |
| Loss on disposal of property and equipment | 4 | 66 |
| Changes in operating assets and liabilities: | ||
| Notes receivable | (1,147) | (4,028) |
| Accounts receivable | (10,806) | (5,257) |
| Inventories | (3,631) | (2,139) |
| Prepaid and other assets | (206) | 520 |
| Income tax payable | 44 | (2,166) |
| Accounts payable | 13 | (245) |
| Other noncurrent liabilities | (47) | 23 |
| Due to related parties | (1) | (83) |
| Accrued expenses and other liabilities | 946 | (1,497) |
| Operating lease liabilities | (744) | (816) |
| Net proceeds from CVR liability settlement | 25 | — |
| Net cash provided by (used in) operating activities | 1,010 | (3,641) |
| Investing Activities | ||
| Acquisition of intangible assets | (733) | (813) |
| Purchase of certificates of deposit | (14,010) | (15,471) |
| Purchase of property and equipment | (1,190) | (2,315) |
| Proceeds from sale of equipment | 30 | 401 |
| Purchase of equity method investment | — | (1,686) |
| Maturity of certificates of deposit | 15,429 | — |
| Net cash used in investing activities | (474) | (19,884) |
| Financing Activities | ||
| Offering costs paid | (1,487) | (536) |
| Proceeds from the issuance of common stock in ATM program | 509 | 773 |
| Proceeds from the exercise of stock options | 2,356 | 1,865 |
| Proceeds from the issuance of common stock in a public offering | 23,000 | — |
| Net cash provided by financing activities | 24,378 | 2,102 |
| Effect of exchange rate changes on cash and cash equivalents | 343 | (273) |
| Net increase (decrease) in cash and cash equivalents | 25,257 | (21,696) |
| Cash and cash equivalents at beginning of the period | 11,813 | 33,509 |
| Cash and cash equivalents at end of period | $37,070 | $11,813 |
| Supplemental Disclosure of Non-Cash Financing and Investing Activities: | ||
| Right-of-use asset obtained in exchange for operating lease liabilities | $63 | $2,017 |
| Convertible preferred stock conversion | $— | $64,525 |
| Supplemental Disclosure of Cash Flow Information: | ||
| Cash paid for income taxes | $5,621 | $8,518 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.